Genprex

Monthly Archives: May 2021

Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series

Investor presentation to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer

Read More

Genprex, Inc. CEO discusses how their “Immunogene Therapy” Drug REQORSA, Modulates Apoptosis

Genprex’s President and CEO, Rodney Varner, sits down with CEO/CFO Magazine to talk about Genprex, how it is reprogramming the course of cancer and diabetes and key catalysts in the next 6-12 months.

Read More

Genprex to Participate in Upcoming May Investor Conferences

Investor presentations to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer

Read More

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer

Amendment to existing worldwide, exclusive license agreement expands Genprex’s oncology franchise

Read More


Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Acclaim-2 Clinical Trial Combines REQORSA™ immunogene therapy with Merck & Co’s Keytruda®

Read More